AR046765A1 - Prolinilarilacetamidas - Google Patents

Prolinilarilacetamidas

Info

Publication number
AR046765A1
AR046765A1 ARP040104656A ARP040104656A AR046765A1 AR 046765 A1 AR046765 A1 AR 046765A1 AR P040104656 A ARP040104656 A AR P040104656A AR P040104656 A ARP040104656 A AR P040104656A AR 046765 A1 AR046765 A1 AR 046765A1
Authority
AR
Argentina
Prior art keywords
hal
mono
coor3
coo
unsubstituted
Prior art date
Application number
ARP040104656A
Other languages
English (en)
Spanish (es)
Inventor
Werner Dr Mederski
Christos Dr Tsaklakidis
Dieter Dr Dorsch
Bertram Dr Cezanne
Johannes Dr Gleitz
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR046765A1 publication Critical patent/AR046765A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ARP040104656A 2003-12-16 2004-12-15 Prolinilarilacetamidas AR046765A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10358814A DE10358814A1 (de) 2003-12-16 2003-12-16 Prolinylarylacetamide

Publications (1)

Publication Number Publication Date
AR046765A1 true AR046765A1 (es) 2005-12-21

Family

ID=34683363

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104656A AR046765A1 (es) 2003-12-16 2004-12-15 Prolinilarilacetamidas

Country Status (16)

Country Link
US (1) US7732481B2 (cg-RX-API-DMAC7.html)
EP (1) EP1697318B1 (cg-RX-API-DMAC7.html)
JP (1) JP4800969B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060113729A (cg-RX-API-DMAC7.html)
CN (1) CN1894210A (cg-RX-API-DMAC7.html)
AR (1) AR046765A1 (cg-RX-API-DMAC7.html)
AT (1) ATE406350T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004299197B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0417630A (cg-RX-API-DMAC7.html)
CA (1) CA2549589A1 (cg-RX-API-DMAC7.html)
DE (2) DE10358814A1 (cg-RX-API-DMAC7.html)
ES (1) ES2310772T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA06006740A (cg-RX-API-DMAC7.html)
RU (1) RU2006125509A (cg-RX-API-DMAC7.html)
WO (1) WO2005058817A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200605841B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1818330A1 (de) * 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
PL2051975T3 (pl) * 2006-05-16 2013-01-31 Boehringer Ingelheim Int Podstawione prolinamidy, ich wytwarzanie oraz ich zastosowanie jako środków leczniczych
BRPI0813230A2 (pt) * 2007-06-28 2014-12-23 Novartis Ag Moduladores de calicreína 7
WO2011027888A1 (ja) * 2009-09-07 2011-03-10 大日本住友製薬株式会社 ジアミド-フェニル誘導体、またはその薬学的に許容される塩
CN109761957B (zh) * 2019-01-18 2020-05-19 西安交通大学 一种含有羟脯氨酸的化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
PL377633A1 (pl) 2003-04-03 2006-02-06 Merck Patent Gmbh Związki karbonylowe
WO2004087696A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Pirazolidin-1,2-dicarbonsaüre-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate

Also Published As

Publication number Publication date
KR20060113729A (ko) 2006-11-02
WO2005058817A1 (de) 2005-06-30
ATE406350T1 (de) 2008-09-15
US7732481B2 (en) 2010-06-08
US20070185189A1 (en) 2007-08-09
AU2004299197A1 (en) 2005-06-30
DE502004007959D1 (de) 2008-10-09
JP2007513988A (ja) 2007-05-31
MXPA06006740A (es) 2006-08-18
RU2006125509A (ru) 2008-01-27
BRPI0417630A (pt) 2007-03-27
CN1894210A (zh) 2007-01-10
AU2004299197B2 (en) 2010-08-05
ZA200605841B (en) 2007-10-31
DE10358814A1 (de) 2005-07-21
CA2549589A1 (en) 2005-06-30
ES2310772T3 (es) 2009-01-16
EP1697318B1 (de) 2008-08-27
JP4800969B2 (ja) 2011-10-26
EP1697318A1 (de) 2006-09-06

Similar Documents

Publication Publication Date Title
AR043833A1 (es) Derivados de 1,2 diazol. metodo de preparacion y composiciones farmaceuticas
AR044818A1 (es) Acidos pirrolidin 1-2 dicarboxilicos-1-[4-(etinil-fenil)amida]-2-[(fenil)-amido] derivados y procedimiento para preparar dichos compuestos
CL2004000720A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLIDINA-1,2-DICARBOXILDIFENILAMIDA, INHIBIDORES DE LOS FACTORES DE COAGULACION Xa, VIIa; PROCESO DE PREPARACION; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; KIT FARMACEUTICO; Y SU USO PARA TRATAR TROMBOSIS, INFAR
AR066972A1 (es) Derivados azapeptidicos
AR036114A1 (es) Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes
AR056986A1 (es) Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
SE0302487D0 (sv) Novel compounds
PE20130152A1 (es) Derivados de heterociclo biciclicos como inhibidores de proteina quinasa b
PE20040197A1 (es) Pirazolopiridinas sustituidas con carbamato
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
SE0302486D0 (sv) Novel compounds
PE20110568A1 (es) Agentes terapeuticos 414
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20080074A1 (es) Derivados de amida como agentes inhibidores de la quinasa c-fms
AR037418A1 (es) Derivados de benzotiazol
AR046643A1 (es) Derivados de pirrol
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
SE0302324D0 (sv) Novel compounds
AR045733A1 (es) Derivados de aminobencimidazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure